Detalles de la búsqueda
1.
Prescription opioid dispensing patterns among patients with schizophrenia or bipolar disorder.
BMC Psychiatry;
24(1): 244, 2024 Apr 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38566055
2.
Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended-release naltrexone in a residential setting.
Am J Addict;
31(2): 142-147, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35137481
3.
Patterns of withdrawal in patients with opioid use disorder (OUD) transitioning from untreated OUD or buprenorphine treatment to extended-release naltrexone.
Am J Drug Alcohol Abuse;
47(6): 753-759, 2021 Nov 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34752714
4.
Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended-Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens.
Am J Addict;
29(4): 313-322, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32246728
5.
Psychoeducational Strategies During Outpatient Transition to Extended-Release Naltrexone for Patients With Opioid Use Disorder.
J Am Psychiatr Nurses Assoc;
25(4): 272-279, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30569814
6.
Antagonists in the medical management of opioid use disorders: Historical and existing treatment strategies.
Am J Addict;
27(3): 177-187, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29596725
7.
The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid-dependent volunteers.
Addict Biol;
21(4): 895-903, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-25975386
8.
A review of a national training initiative to increase provider use of MAT to address the opioid epidemic.
Am J Addict;
25(8): 603-609, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-28051841
9.
Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine-maintained heroin users.
Addict Biol;
20(4): 784-98, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25060839
10.
Baseline characteristics of patients predicting suitability for rapid naltrexone induction.
Am J Addict;
24(3): 258-264, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25907815
11.
Mast cell tryptase reduces junctional adhesion molecule-A (JAM-A) expression in intestinal epithelial cells: implications for the mechanisms of barrier dysfunction in irritable bowel syndrome.
Am J Gastroenterol;
108(7): 1140-51, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23588236
12.
Comparison of a drug versus money and drug versus drug self-administration choice procedure with oxycodone and morphine in opioid addicts.
Behav Pharmacol;
24(5-6): 504-16, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23839029
13.
Effects of repeated oxycodone administration on its analgesic and subjective effects in normal, healthy volunteers.
Behav Pharmacol;
23(3): 271-9, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22495183
14.
Patient characteristics associated with initiation of XR-naltrexone for opioid use disorder in clinical trials.
Drug Alcohol Depend;
233: 109343, 2022 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35131528
15.
A pilot study of neurocognitive function in older and younger cocaine abusers and controls.
Am J Addict;
20(3): 228-39, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-21477051
16.
A comparison of independent depression and substance-induced depression in cannabis-, cocaine-, and opioid-dependent treatment seekers.
Am J Addict;
20(5): 441-6, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-21838843
17.
The association between naltrexone treatment and symptoms of depression in opioid-dependent patients.
Am J Drug Alcohol Abuse;
37(1): 22-6, 2011 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-21192125
18.
Evaluation of Opioid Overdose Reports in Patients Treated with Extended-Release Naltrexone: Postmarketing Data from 2006 to 2018.
Drug Saf;
44(3): 351-359, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33258068
19.
Prescription use disorders in older adults.
Am J Addict;
19(6): 515-22, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-20958847
20.
Cognitive performance of patients with opioid use disorder transitioned to extended-release injectable naltrexone from buprenorphine: Post hoc analysis of exploratory results of a phase 3 randomized controlled trial.
Addict Behav;
111: 106538, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32777606